Biologically Active Substance – Page 24

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

10 months ago talkbio0Tagged AMT-130, cUHDRS, Disease Progression, gene therapy, Huntington 's disease, Huntington 's Disease Rating Scale, Identifier, neurofilament protein L, NfL, Phase I/II trials, Regenerative Medicine, RMAT, Unified - Type of Agreement, UniQure

uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation

FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option

10 months ago talkbio0Tagged Alzheimer 's disease, Amyloid, anti-amyloid monoclonal antibody, Approved, Donanemab, Eli, Eli Lilly, Kisunla, Mental deterioration, Plaque (lesion), United States Food and Drug Administration

Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options